EAY191-N2 Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1 A ComboMATCH Treatment Trial
This is a research study called the EAY191-N2 Phase 2 Trial. It is trying to figure out if a combination of two drugs, Fulvestrant and Binimetinib, can help people who have Hormone Receptor-positive breast cancer. The study is specifically looking at patients who have certain genetic changes in a gene called NF1. These changes are called Frameshift or Nonsense Mutation or Genomic Deletion. The goal of this trial, which they call "ComboMATCH Treatment Trial," is to find out if this drug combination is a good match for treating this specific type of breast cancer in people with these genetic changes. They want to see if it helps these patients.
Hormone Receptor-Postitive: It is a type of breast cancer where the cancer cells have receptors on their surface that can attach to hormones in the body, particularly estrogen and/or progesterone. When these receptors attach to hormones, they can stimulate the cancer cells to grow.
For more information about the trial, click the link below:
Clinical Trial Site: Einstein
To see all available clinical trials click here.